Alendronic acid/colecalciferol

From Wikipedia, the free encyclopedia

Alendronic acid/colecalciferol
Combination of
Alendronic acidBisphosphonate
ColecalciferolVitamin
Clinical data
Trade namesFosamax Plus D, Fosavance, Adrovance, others
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Alendronic acid/colecalciferol, sold under the brand name Fosamax Plus D among others, is a medication for the treatment of osteoporosis in men or in postmenopausal women.[2][1][3][5]

Alendronic acid/colecalciferol was approved for use in the United States and in the European Union in 2005.[6][4]

References[]

  1. ^ a b "Fosavance Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 1 March 2020.
  2. ^ a b "Fosamax Plus D- alendronate sodium and cholecalciferol tablet". DailyMed. 16 August 2019. Retrieved 1 March 2020.
  3. ^ a b "Adrovance EPAR". European Medicines Agency (EMA). 26 February 2020. Retrieved 1 March 2020.
  4. ^ a b "Fosavance EPAR". European Medicines Agency (EMA). 9 October 2019. Retrieved 1 March 2020.
  5. ^ Von Schacht E, Dambacher MA, Ringe JD, Dukas L (April 2012). "[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence]". MMW Fortschritte Der Medizin (in German). 154 (Suppl 1): 10–21. PMID 23427364.
  6. ^ "Drug Approval Package: Fosamax Plus D (Alendronate Sodium) NDA #021762". U.S. Food and Drug Administration (FDA). 8 June 2006. Retrieved 1 March 2020.

External links[]


Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""